Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects head and neck cancer treatment

NICE has published guidance on cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck

The UK National Institute for Health and Clinical Excellence (NICE) has published guidance on cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck. The guidance does not recommend it as a treatment option for patients with this type of cancer.

Squamous cell cancer of the head and neck is cancer of the epithelium (lining cells) of the mouth, nose, throat and surrounding areas.

People currently receiving cetuximab in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck should have the option to continue treatment until they and their clinician consider it appropriate to stop.

Andrew Dillon, NICE chief executive, said: "When reaching today's decision, the appraisal committee took account of all of the available evidence on the use of cetuximab, in combination with platinum-based chemotherapy, when compared to the existing treatment options already available to patients with metastatic squamous cell head and neck cancer. The committee noted the existing uncertainty over the clinical effectiveness of the treatment and the costs of the treatment when compared to those currently available. The manufacturer's cost-effectiveness analysis resulted in the cost of an additional 'quality adjusted life year' from treatment with cetuximab plus platinum-based chemotherapy compared with platinum-based chemotherapy alone to be £121,367, with a predicted gain in overall survival of just over two months. This would mean the NHS making significant funds available for a very expensive treatment, which may or may not benefit individual patients. Those funds would not then be available for treating other conditions with greater and more certain benefits for other patients.

"The committee also took into account the supplementary advice provided by NICE to be taken into account when appraising treatments at the end of life. The committee noted that cetuximab was used for a small population with a short life-expectancy for a devastating disorder but it did not offer sufficiently greater benefits to these patients compared to existing treatments."

24th June 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

OPEN Health Graduates and the XP Support Group
During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...
Alexander Devine Website has gone live!
As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics